Arctic Therapeutics
CompanyIceland
Arctic Therapeutics develops 6 assets, the furthest in phase 3 (NPI-001 in retinitis pigmentosa). Mostly small molecule and peptide acting on Oxidative stress and ROS signalling, CLEC16A and CDHR3; based in Iceland.
- 6
- Assets
- Furthest stage
- Phase 3
- Raised
- €26.5m
- 2
- Trials
- 2
- Signals
Pipeline
6Replenishes intracellular glutathione to reduce oxidative stress and protect retinal photoreceptors.
Phase 3, Small molecule, Oxidative stress and ROS signalling, retinitis pigmentosa, usher syndrome
Targets the non-neuronal cholinergic system to promote anti-inflammatory and repair activities in skin.
Phase 2, acne vulgaris, atopic dermatitis
Human trials
3 more assets
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials2
- Funding rounds and grants1
- People15
- Signals3
- Similar companies6